close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neuronetics, Inc. - Common Stock (NQ:STIM)

1.340 +0.040 (+3.08%)
Streaming Delayed Price Updated: 3:15 PM EST, Nov 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neuronetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Neuronetics Showcases New NeuroStar® TMS Findings at Clinical TMS Society Annual Meeting
Data highlights the Company’s commitment to advancing TMS and improving patient outcomes 
From Neuronetics
Via GlobeNewswire
News headline image
NeuroStar® Expands “Tap Into Possibility” Campaign in Honor of Mental Health Awareness Month
Campaign features patients’ experiences to support others with depression 
From Neuronetics
Via GlobeNewswire
News headline image
Neuronetics Announces Lisa Metzner-Rosas as SVP, Chief Marketing Officer
Strategic role strengthens NeuroStar® Advanced Therapy commercialization team 
From Neuronetics
Via GlobeNewswire
News headline image
Neuronetics's Return On Capital Employed Overview ↗
 
Via Benzinga
News headline image
Preview: Neuronetics's Earnings ↗
 
Via Benzinga
News headline image
Neuronetics Inks Six-Year Exclusive Partnership With Greenbrook TMS ↗
 
Via Benzinga
News headline image
Neuronetics Announces Expanded TMS Access through United HealthCare
UHC Medicare Advantage plans in NGS states expand access via NPPs 
From Neuronetics
Via GlobeNewswire
News headline image
Neuronetics Announces Continued Momentum for Expanded Health Insurance Coverage for TMS Therapy
BlueCross BlueShield of Mississippi Latest to Allow Non-Physician Practitioners to Prescribe TMS 
From Neuronetics
Via GlobeNewswire
News headline image
NeuroStar® Advanced Therapy Enhanced With Wi-Fi Capabilities
Fifth FDA clearance in less than two years offers greater connectivity and flexibility to improve the patient and provider experience 
From Neuronetics
Via GlobeNewswire
News headline image
Neuronetics's Return On Capital Employed Overview ↗
 
Via Benzinga
News headline image
Short Volatility Alert: Neuronetics, Inc. ↗
On Thursday, shares of Neuronetics, Inc. (NASDAQ: STIM) experienced volatile short activity. After the activity, the stock price went down -1.74% to $2.83. The overall sentiment for STIM has been... 
Via Benzinga
News headline image
NeuroStar® Advanced Therapy Receives Patient Impact Award from Life Sciences PA
Award recognizes NeuroStar for its significant contributions toward patient wellbeing 
From Neuronetics
Via GlobeNewswire
News headline image
Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank ↗
The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the... 
Via Benzinga
News headline image
Neuronetics Announces TMS Coverage Criteria Changes for Over 23 Million Covered Lives
United HealthCare Optum Reduces Barriers to TMS Eligibility for Depression Patients 
From Neuronetics
Via GlobeNewswire
News headline image
Neuronetics Expands NeuroStar® Advanced Therapy’s Proprietary TrakStar® Platform
Company Launches a New Educational Campaign For Providers 
From Neuronetics
Via GlobeNewswire
News headline image
Neuronetics Sponsors the 5th International Brain Stimulation Conference
Poster Session Highlights the Strong Dose-Response Relationship and the Importance of Treating Beyond 30 Treatments With NeuroStar Advanced Therapy 
From Neuronetics
Via GlobeNewswire
News headline image
Neuronetics Announces Elevation of Sara Grubbs to SVP, Chief Revenue Officer
New Senior Leadership Role Will Streamline Alignment of All Company Revenue-Generating Functions 
From Neuronetics
Via GlobeNewswire
News headline image
Neuronetics Announces Updated Medicare Policy Expanding Access to NeuroStar TMS Therapy through Nurse Practitioners
NGS MAC Allows Non-Physician Practitioners with Autonomy to Prescribe TMS 
From Neuronetics
Via GlobeNewswire
News headline image
Neuronetics Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar® Advanced Therapy for Mental Health
Peer-reviewed publication shows NeuroStar TMS as an effective non-drug treatment for depression with comorbid anxiety 
From Neuronetics
Via GlobeNewswire
News headline image
Neuronetics Settles Unfair Competition Related Litigation Against BrainsWay ↗
 
Via Benzinga
News headline image
Neuronetics Announced as a Winner by 2022 Merit Awards for HealthCare in the Patient Care Category
NeuroStar’s technology once again recognized as an effective non-drug treatment for patients 
From Neuronetics
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  During Thursday's session, 108 stocks hit new 52-week highs. 
Via Benzinga
News headline image
Neuronetics Announces NeuroStar® Advanced Therapy for Mental Health System Innovations
Enhancements further establish the Company’s leadership position as the top transcranial magnetic stimulation therapy 
From Neuronetics
Via GlobeNewswire
News headline image
Neuronetics Announced as Winner by 2022 Merit Awards for Technology
NeuroStar technology is acknowledged for its innovation and accessibility as a non-drug treatment for mental health 
From Neuronetics
Via GlobeNewswire
News headline image
Neuronetics Announces Updated TMS Coverage Policies That Will Expand Patient Access to NeuroStar TMS Therapy for Mental Health
Published and Proposed Medicare Coverage through CGS and NGS MACs Will Reduce Number of Medication Trials, Leading to Increased Eligibility for TMS 
From Neuronetics
Via GlobeNewswire
News headline image
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday ↗
Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Gainers 9 Meters Biopharma (NASDAQ:NMTR) stock moved upwards by 22.8% to $0.25 during Tuesday's pre-market session. The company's market cap stands at $65.8 million. 
Via Benzinga
News headline image
Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today